Envoy Medical Inc. (COCH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Envoy Medical Inc. stock (COCH) is currently trading at $0.68. Envoy Medical Inc. PS ratio (Price-to-Sales) is 286.97. Analyst consensus price target for COCH is $7.00. WallStSmart rates COCH as Sell.
- COCH PE ratio analysis and historical PE chart
- COCH PS ratio (Price-to-Sales) history and trend
- COCH intrinsic value — DCF, Graham Number, EPV models
- COCH stock price prediction 2025 2026 2027 2028 2029 2030
- COCH fair value vs current price
- COCH insider transactions and insider buying
- Is COCH undervalued or overvalued?
- Envoy Medical Inc. financial analysis — revenue, earnings, cash flow
- COCH Piotroski F-Score and Altman Z-Score
- COCH analyst price target and Smart Rating
Envoy Medical Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Envoy Medical Inc. (COCH) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
Envoy Medical Inc. (COCH) Key Strengths (0)
Supporting Valuation Data
Envoy Medical Inc. (COCH) Areas to Watch (6)
Losing money on operations
Revenue declining -25.00%, a shrinking business
Very expensive at 287.0x annual revenue
Very low institutional interest at 5.18%
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.2x book value
Supporting Valuation Data
Envoy Medical Inc. (COCH) Detailed Analysis Report
Overall Assessment
This company scores 11/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (286.97), Price/Book (4.22) suggest expensive pricing. Growth concerns include Revenue Growth at -25.00%, which may limit upside. Profitability pressure is visible in Operating Margin at -13590.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -13590.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -25.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
COCH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
COCH's Price-to-Sales ratio of 286.97x trades at a deep discount to its historical average of 1322.64x (17th percentile). The current valuation is 91% below its historical high of 3357.46x set in Aug 2023, and 29% above its historical low of 222.07x in Jan 2026. Over the past 12 months, the PS ratio has compressed from ~464.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Envoy Medical Inc. (COCH) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Envoy Medical Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 208,000 with 25% decline year-over-year.
Key Findings
Spending 2189% of revenue (5M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 25% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.06, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Envoy Medical Inc..
Bottom Line
Envoy Medical Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Envoy Medical Inc.(COCH)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Envoy Medical Corporation manufactures and markets an implantable hearing aid device. The company is headquartered in White Bear Lake, Minnesota.